Cofactor Genomics Launches ImmunoPrism™ Immune Profiling Kit, for Use in Clinical Sequencing Laboratories --Enables in-house, RNA-based, solid tumor profiling with powerful, cloud-based informatics tools to inform critical clinical decisions-- SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cofactor...

Cofactor Genomics Announces Clinical Validation of its Tumor Immune-Profiling Assay, ImmunoPrismTM CAP/CLIA validation of ImmunoPrismTM furthers Cofactor’s mission of leveraging RNA to build unique, transformative assays informing critical clinical decisions SAN FRANCISCO, Oct. 02, 2018 (GLOBE...

Cofactor Genomics announces new collaboration with the National Cancer Institute (NCI) to demonstrate power of RNA-based immune profiling assay SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, leading developer of advanced RNA analysis tools, announced today that they have entered into an agreement with the National...

Cofactor Genomics Launches Paragon, a Comprehensive Quantitative Solid Tumor Immune Profiling Assay SAN FRANCISCO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the commercial launch of Paragon, a solid tumor...